Categories
Junk Sciences Junk Sciences Sciences Uncategorized

[Sciences/Junk Sciences] Reconsideration of the immunotherapeutic pediatric safe dose levels of aluminum (Lyons-Weiler and Ricketson, J Trace Elem Med Biol 2018)

This is a post I wanted to write about a long time ago but for some reasons, I have been putting on the back burner for many different reasons.
You know what can be the most irritating to read? Papers from anti-science in general. You see, if the data was sound, the experimental setup was robust then I would consider their arguments are valid and sound. The problem with the anti-science papers I have been reading so far (anti-vaccines, anti-GMOs) are most of the time written by scientists that are lacking the expertise and credentials (in terms of publication record) to discuss on a topic, are based on speculation (the experimental data to support their hypothesis is at best paper-thin), the experimental data are most of the time missing the rigor and paradigm needed to make an objective outcome and often cherry-pick the literature.
Under normal conditions, such papers would not even pass a normal peer-review filter and would have been rejected outright. Yet, such papers found their way in very low impact factor journals or in predatory journals (that will publish any garbage study, as long as there is a valid payment method).

1. Who are the authors?
This is the case of this manuscript written by James Lyons-Weiler and Robert Ricketson. In this study, they claim that the current immunization schedule is dangerous, blaming on the extraordinary amount of aluminum and using questionable and speculative pharmacokinetics to support their claims (of course, there is no experimental data to support their claims, only speculation). A tenet in scientific publication is to assess how credible the authors are in the field, this can be judged by the authors affiliation and publication records. James Lyons-Weiler has  (according to his LinkedIn profile) a PhD in Ecology, Evolution and Conservation Biology and currently affiliated to the “Instittute for Pure and Applied Knowledge”. This is not a scientific institute as the Salk Institute, but rather an frontstore for some quackery posing as a “scientific institute”. The second author, Robert Ricketson, is no better. Indeed, he is even worse. Apparently Dr. Ricketson has a history of medical malpractice as a spine surgeon, and has been implicated in a medical malpractice lawsuit in 2001 for inserting a screwdriver in a patient spine. At the publication date, Ricketson affiliation is another “scientific institute” named “Hale O’mana’o Research” in Edmond, OK. A quick verification on his LinkedIn profile suggest that these two Ricketson are the same Ricketson. To summarize, we have two authors with ZERO expertise in pharmacokinetics (including one doctor that got fined over $5 millions for medical malpractice), working in institutes with questionable scientific credientials but established anti-vaccine stance, under the disguise of “vaccine safety” (here and here), published in a journal in which a notorious anti-vaccine scientist is sitting in the editorial board. Is it surprising? For me, it is not. Just a classical MO for anti-vaccine scientist.

2. What the paper is about?
You can find the paper here, since it is behind paywall I cannot legally share the information, so I would request the reader to corroborate my claims by getting the full-text. In this study, the authors consider the safety studies done in animals are not correct and underestimate the toxicity of aluminum because they are based on animal body weight. And thats where the trouble start. The authors solely consider the amount of aluminum injected into animals and patients SOLELY based on the body weight.
They ignore the administration route, they ignore the existing literature and even questions the outcomes and recommendation of the World Health Organization as mentioned as “We found two important errors in the provenance and derivation of provisional aluminum intake levels from World Health Organization (WHO; Supplementary Material) which, unfortunately, led to overestimation of safe exposure levels.” That’s a bold statement by the beginning, coming from two non-experts in pharmacokinetics and toxicokinetics.
So how do they ended up using such claim? By using a derived version of the Clarke’s equation:

Child dose (mg) = Adult Dose (mg) * (child bodyweight (lbs)/adult bodyweight (lbs))

The Clarke’s equation is a common equation used for therapeutic dosing, as we commonly refer to administer doses as x mg/kg. Knowing the patient weight, you can easily calculate the dose administered.  This formula is great…….if you already know the target concentration (or the average plasma concentration) you aim to target. This is usually supported by empirical data and further confirmed by lab tests (you can dose the drug in the patient plasma and assess if such amount falls within the therapeutical window). But this equation tells you nothing about the pharmacokinetics of the drug, or about the bioavailability of the drug, or differences in the administration routes.
It only tells you one thing “How many miligrams of X should I administer to obtain a plasma concentration of X falling into therapeutical range?” That’s it. You assume a dosing regimen (mg/kg), you know your patient weight (in kgs) and thus you can obtain the dose needed (loading dose or maintenance dose).  However, the authors manipulated the equation to be able to transpose the minimal risk level from adults to children as the following:

CED (mg/kg)= HED(adult) mg/kg x [BW(child) (kg)/BW(adult) (kg)]

The rest of the paper is SOLELY based on speculation, no experimental data to support the claim (we rather have a post hoc ergo fallacy unfolding). If the authors wanted to make their claims valid, they would provide experimental data (in forms of blood sampling) for 2 months babies before immunization (baseline control) and 6-24 hours after immunization to show that Al levels in plasma are significantly altered by the immunization. But they never show that data.
Indeed, what they show is a blatant misuse of the data and recommendation of the FDA and a serious miscalculation that a 12th grader would not even do.
They compared the dietary MRL as “JECFA provisional tolerable daily intake from dietary and additive exposures of 140 μg/kg/day and current provisional tolerable daily intake of 290 μg/kg/day per day both before and after the safety factor of 10 is applied (Fig. 3).
We end up in the classical cases of “apples versus oranges” and trying to make the claim they are the same. Which they are not. Yes, both are extravascular routes and follow similar fate. But in the same time, we have to compare the physics-chemical aspects and the bioavailability of Al in both routes. One is administered by oral route, the other by intramuscular route. In both cases, the bioavailability falls within the same range, with the oral showing about 0.3% and the IM from 0.6% (based on Flarend et al., Vaccine 1997) and 0.9% (Yokel and McNamara estimate, Pharm Tax 2001).

What the authors show us is basically a graph that assume the WHOLE Al injected in 100% bioavaialable at once, exceeding the MRL adjusted to pediatrics) as seen in Figure 4:
Lyons_Weiler_2018_Fig4

There is one thing to consider: The ATSDR. The ATSDR considers the MRL of 1mg/kd/day of ingested aluminum (that is about 100x lower than the NOAEL and adjusted to the bioavailability, as described here: https://www.atsdr.cdc.gov/toxprofiles/tp22-c8.pdf). If we assume a bioavailability of 0.3%, then we expect that out of 1mg/kg/day ingested, we can estimate that about 3microg (or 0.003mg)/kg/day would contribute in the total burden in the Al plasma level. This graph would be correct if 100% of the aluminum injected ended up in the systemic circulation at ONCE and spiked Al levels significantly high. But thats not the case, and the authors blatantly ignored this critical information, coming from previous studies. In order to compare these two items, you have to compare and estimate how much of each of these routes will contribute in the total Al plasma/blood levels.
You cannot just plot the total amount injected (adjusted per kg) and assume it is representing the same variable than estimated plasma levels from the MRL. Now, let consider that the Al injected is available at the rate of 1% a day, the graph will look more like that.

Lyons_Weiler_2018_Fig4_Adjusted

You see, we have a complete different scenario. If we consider that the aluminum is slowly released into the body at a rate of 1% per day we are now being way under the MRL and within safe levels. Again, we consider the MRL of 1mg (1000microg)/kg/day. If we consider a 0.3% bioavailability and difference in 5th and 95th percentiles weight (grey bars), we conclude that the daily burden of Al via dietary route should not exceed a value ranging from 13.20-18.72microg/day. Our values matches the MRL from Lyons-Weiler. In other words, our assumption is correct. If we consider an average weight of 5.35kg (50th percentile) at 2 months and 1mg as a cumulative dose of the immunization occurring the same day (conservative estimate), the amount delivered that day would be 0.187mg or (187microgram). Considering a bioavailability of 1% per day via IM, we have about 1.87microgram of burden from the vaccine added each day to a maximum MRL of 16.05microgram/day for the 50th percentile (weight 50th percentile=5.35kgs). Thats about 11.7% aluminum to be removed from the daily MRL, but within negligible range to have a statistical significance (you need at least 30% to consider it as statically meaningful).  This of course has to be confirmed by studies assessing plasma levels of Al after injections but there are already a literature out there with such data avaialable and reported here and here. Both studies concluded no changes in total Al plasma levels in regard of the vaccination status, including 6-24 hours after immunization.

3. Concluding remarks

Anti-science know how to bangs for their bucks, by sensationalizing claims knowing that the lay person will not or be capable to verify their claim. Most of the times, such claims come from persons that are legitimate scientists in their field, but completely speak out of their expertise domain. This is a common trope we see when people cite Linus Pauling, Otto Warburg or Luc Montagnier. Each of them have done remarkable discoveries in their field, got their Nobel Prizes but once they speak outside their expertise have proven to be wrong or have seen their claims manipulated by quack-peddlers. Lets take Linus Pauling that has been incremental in modern chemistry by describing the chemical bonds, but later claimed cancer(s) can be cured with Vitamin C. Coincidentaly, he died of prostate cancer in 1994.
Same applies in this paper. We have two authors with ZERO knowledge of pharmacokinetics, yet they have given themselves the role to demonize aluminum at all cost, bending and occulting facts to fit their narrative and their conclusion. This paper is the evidence that they are not serious about “vaccine safety”. They are staunch anti-vaccines, and they will use their status of scientists to vilify it at all costs, even if it means reaching outside their expertise, make extraordinary claims without extraordinary evidences (they did not have evidence for this study) and get published in a journal that will favor their claims and obviously lacked the rigor in the review.
Negating the neurotoxic effects of aluminum is not a correct statement either. Aluminum is neurotoxic, but as anything in toxicology it is all about the dose. And one parameter that is critical to assess the safety of aluminum is its plasma level. This safety level is driven by how much aluminum access the systemic circulation (from IV parenteral nutrition bags or from extravascular routes such as vaccines or dietary exposure). What matter at the end is the Al plasma levels and the FDA set a limit on that daily exposure (5 micrograms/kg/day via IV route). This is a problem encountered by patients suffering from non-functional kidneys (95% of aluminum is cleared via renal route) and from patient continuously fed via IV route (total parenteral nutrition).
Both Lyons-Weiler and Ricektson failed to applied basic concepts of pharmacokinetics, ignored the differences between vascular and extravascular routes and willfully used a calculation method that is not appropriated for this purpose. I would even what is worse is that none of their claims is supported by hard data, making their claims even more questionable.
Unfortunately, such “junk paper” felt through the cracks of peer-review and has been used repeatedly used by anti-vaxxers as supporting evidence. As Andrew Wakefield has his second paper removed after 16 years, how long it will take to remove that paper?
I dont know but the damage is done, and until “vaccine safety” scientists come with robust and foul-proof studies published in highly respected journals, they will be considered by me and others as junk scientists, keeping on feeding the literature with their garbage studies that should have been wiped out by a rigorous peer-review process.

 

10 replies on “[Sciences/Junk Sciences] Reconsideration of the immunotherapeutic pediatric safe dose levels of aluminum (Lyons-Weiler and Ricketson, J Trace Elem Med Biol 2018)”

So VP indeed deleted the original post about aluminum, macrophages and BBB from three years ago and replaced with something completely different? Thank God, The Internet Archive “Wayback Machine” exists! Wow! Simply wow.

Like

If the aluminium compounds used in adjuvants were so bioavailable that an intramuscular injection was immediately 100% bioavailable, then they would be *no use at all as adjuvants*. I mean, the whole reason they work as a way of leveraging an antigen (and reducing the amount of antigen that’s injected) is that they *hang around for a long time*.

The “Institute for Pure and Applied Knowledge” sounds like something that the villain from a Bond movie might set up. It is not Jamie L-W’s affiliation. It is Jamie L-W.

Like

Thanks for the clarification. I agree, if these aluminum adjuvants were dissolving at once, their function as adjuvants would be meaningless (my understanding is that it helps to fold and expose antigens on their surface making it easier to act as epitopes).
Now, for the IPAK, I am learning something new here. Wow. Simply wow. I guess it rivals in its James Bond villainy with the infamous IRT, chaired by a certain flying yogi.

Like

I find it odd that they reference Mitkus et al. (2011) to say that the wrong MRL was used in the updated aluminum pharmacokinetics, so they (hopefully) actually read through the detailed analysis provided in Mitkus. However they apparently ignore *all* of the other calculations Mitkus included, like the estimated rate in which aluminum is released from the IM injection site and into the bloodstream.

Liked by 1 person

Exactly, at least the Mitkus paper has the pharmacokinetics more correct: they used a three-compartment model (inclusive of the bone tissue and soft tissue), which surprisingly did not bother Lyons-Weiler and Ricketson (there is a paper from Weisser and colleagues that is even more accurate, inclusive of citrate and transferrin-bound). This is a gross negligence from the authors. If their point was to demonstrate that aluminum load in infants was indeed higher, they would have provided experimental data that show their model was accurate in prediction.
Now, when you include the bioavailability factor (since it is an IM injection site) and using the estimate from Yokel and colleagues, then the picture is very different from what the article concluded. Also my method, far from perfect, was still leading to similar outcomes when we applied it to the PO (oral) route.
This is why this paper should not have been published. You cannot brush off the existing literature because it contradicts your claim.

Like

I do love a good analysis and counteranalysis. I have one question though. If the rate of aluminium is only able to pass through IM tissue at 1% per day, doesn’t that prove antivax theory that it remains in tissue for a very, very long time?

Not only that, but transferrin and transferrin receptors are how metals like iron are bound to blood travelling to the brain and delivered, which Alum is able to use since it can mimic a similarly charged ferric cation.

Either the rate it is absorbed into the bloodstream is higher and breaching safety limits, or it does indeed remain in tissue rather than excreted quickly, which is regularly shouted down as absurd antivax propaganda. Which one is it?

Liked by 1 person

Hi Cameron,
Thank you for your email. You see, this is the limitations of explaining the complicated pharmacokinetics in a very lay term.
The PK profile of pharmacokinetics is indeed very complicated and the minimal model that can help explain it is the three-model pharmacokinetics. AVers see the world as an impossible binary outcome: it is either 100% dangerous or 100% harmless. The zero-risk never exists and in science we discuss about nuances, weighing the pros and cons. If the body was aluminum-free (I mean here no aluminum from dietary intake), it would be a problem. Yet, we are been constantly exposed to aluminum every single day in our food and water. Even if the fraction is small, it is non-negligeable either.
But lets go back to the aluminum. It would be a problem if these aluminum salts had some chemical reactivity in the body. If there were, they would at least induce a state of constant inflammation state at the site of injection. It it was a major concern, it would have been documented by robust and reproducible experiments around the globe. But there is not. There are some scientists like Gherardi or Schoenfeld claiming it happens, citing an ever-changing name (MMF, then ASIA) with a very interesting tropism and localization (MMF appeared to be as much French as was the Minitel). Nobody except Gherardi reported such condition, made with nebulous symptoms (also being said, Gherardi has been trying to use public research fund to finance his startup via the development of the detection kit).
Now, lets talk about transferrin. It seems this is one of the possible mechanism of Al entry in the brain (transferrin and citrate Al). It would be tempting to think that Al compete enough to iron for the Tf binding site. This has to be proven (I have not searched about much this either) but it is also can be solved by stochastic.
Lets assume a transferrin protein has 10 iron binding site. If we assume that both Fe and Al have same affinity to the binding site, the only parameter that would influence the occupation of Tf by aluminum is the relative concentrations in plasma. The aluminum plasma values I found online oscillate below 6 microg/L. The iron plasma values I found online between 400 and 1500 microg/L. You see we are at best talking about 60 times more iron than aluminum. Just by stochastic, the interference of aluminum appears minimal. Thats seems to go with the low brain uptake of Al (~0.6% of plasma concentration) but also may explain the very low clearance of brain Al (Transferrin receptor-mediated transcysosis seems to be mostly polarized, in a blood-to-brain manner).
This is why I repeat based on the current science the following:
1) AH and AP appears as inert molecules and end up dissolved over time. If a severe reaction occurs in the general population, we would have major number of cases reported.
2) What really matters is how much extra burden of aluminum occurs each day. Since these salts are slowly released, they marginally impact the levels of blood aluminum (the fact you need to use 26Al to reach the sensitivity needed tells you something about). The main daily source remains from dietary exposure. The previous use of Al as phosphate-binding agent for patients with renal failure (literarily grams/day) shows us you really need an excessive amount to see changes in plasma levels (unless you directly inject via IV route).
3) What really seems to matters in terms of aluminum neurotoxicity is the amount in plasma. The uptake is very low (0.6%) and the values reported in the literature about neurotoxicity are usually in the range of 10-100micromoles/L. Thats about 260-2600microg/L to achieve in the brain. Unless you have sustained and abnormally high Al plasma levels (as reported in patients with renal failure), the probability of developing neurological conditions must be very minimal.
Hope that helps.

Like

Hi there,

You say:

“In both cases, the bioavailability falls within the same range, with the oral showing about 0.3% and the IM from 0.6% (based on Flarend et al., Vaccine 1997) and 0.9% (Yokel and McNamara estimate, Pharm Tax 2001).”

Just wondering how you calculated the bioavailability from Yokel’s article. How did you arrive at 0.9%?

Thanks in advance!

Liked by 1 person

Hi Dustin,
Thank you very much for your comment. Hopefully you can access the full-text of the reference cited to cross-check my number.
In Table 1, Yokel and McNamara provide a range number of 150-850microg/dose and a daily Al of 1.4-8microg/day. Taking the lowest range, you get 1.4/150=0.0093 or 0.93%. However this is really a gross estimate with several approximation as mentioned in the foonote: “Based on 20 injections in the first 6 years of life and an average weight of 20 kg.”.
I would strongly recommend to stick with the value extrapolated from the Flarend study, because it has much less approximation and directly obtained from the experimental data.
Hope that helps 🙂

Like

Leave a comment